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Comparison of the monoclonal antibodies 17-1A and 323/A3: the influence
of the affinity on tumour uptake and efficacy of radioimmunotherapy in
human ovarian cancer xenografts
E Kievit, HM Pinedo, HMM Schliiper, HJ Haisma and E Boven
Department ofMedical Oncology, Free University Hospital, PO Box 7075, 1007 MB, Amsterdam, The Netherlands.
Summary The low-affinity monoclonal antibody (MAb) chimeric 17-lA(c-17-lA) and the high-affinity MAb
mouse 323/A3 (m-323/A3) were used to study the effect of the MAb affinity on the tumour uptake and efficacy
of radioimmunotherapy in nude mice bearing subcutaneously the human ovarian cancer xenografts FMa,
OVCAR-3 and Ov.Pe. Both MAbs are directed against the same pancarcinoma glycoprotein. In vitro, the
number of binding sites on tumour cells at 40C was similar for both MAbs, but m-323/A3 had an
approximately 5-fold higher affinity (1.3-3.0 x109M-') than c-17-lA (3.0 -.4 x IO' M-). This difference in
affinity was more extreme at 37°C, when no binding of c-17-IA could be observed. MAb m-323/A3 completely
blocked the binding of c-17-lA to tumour cells, whereas the reverse was not observed. Immunohistochemistry
showed a similar but more intense staining pattern ofm-323/A3 in human ovarian cancer xenografts than of c-
17-1A. In vivo, the blood clearance in non-tumour-bearing nude mice was similar for both MAbs with terminal
half-lives of 71.4 h for m-323/A3 and 62.7 h for c-17-lA. MAb m-323/A3 targeted better to tumour tissue, but
was more heterogeneously distributed than c-17-lA. The cumulative absorbed radiation dose delivered by m-
323/A3 to tumour tissue was 2.5- to 4.7-fold higher than that delivered by c-17-lA. When mice were treated
with equivalent radiation doses of ['311]m-323/A3 and ['31I]c-17-lA, based on a correction for the
immunoreactivity of the radiolabelled MAbs, m-323/A3 induced a better growth inhibition in two of the
three xenografts. When the radiation doses were adjusted to obtain a similar amount of radiation in the
tumour c-17-lA was more effective in tumour growth inhibition in all three xenografts.
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The uptake of monoclonal antibodies (MAbs) in tumour
tissue is influenced by a number of factors, including the
MAb affinity. Whether low- or high-affinity MAbs should be
used in tumour diagnosis or therapy is under current
investigation. Theoretically, a MAb with a high affinity has
a higher percentage ofuptake and an increased retention time
in the tumour, although the penetration is limited. As a result
of its efficient binding to the antigen near blood vessels, a
lower percentage of free MAb is available to percolate into
the tumour. Experimental evidence for the presence of a
binding-site barrier for high-affinity MAbs has been
demonstrated by the group of Weinstein (Juweid et al.,
1992). In contrast, MAbs with a low affinity penetrate deeper
into the tumour but show a lower tumour uptake and have a
shorter retention time.
The human antigen encoded by the GA733-2 gene is a 38-
40 kDa transmembrane glycoprotein expressed on the baso-
lateral surface of normal epithelial cells in secretory tissues
(Linnenbach et al., 1993; Momburg et al., 1987). The antigen
is highly expressed in adenocarcinomas, including those from
the colon, breast, ovary and lung (Momburg et al., 1987).
Therefore, the antigen may be a good target for immuno-
scintigraphy and immunotherapy. MAb mouse 17-lA
(Koprowski et al., 1979), the first MAb generated against
this antigen, has been successfully used for radioimmunolo-
calisation of colorectal cancer lesions in patients (Chatal et
al., 1984). The uptake of i.v.-administered 17-lA in normal
tissues was low, indicating that the basal membrane, which is
absent or disrupted in tumours, prevents 17-lA from
reaching the antigen on normal epithelial cells. As 17-lA is
also able to induce antibody-dependent cellular cytotoxicity
(ADCC), colorectal cancer patients have been treated with
unconjugated mouse 17-lA and sporadic responses were
observed (Mellstedt et al., 1991). A reduced recurrence rate
and an increased survival time have been observed in patients
with operable colorectal cancer receiving unconjugated mouse
17-lA as adjuvant therapy (Riethmiiller et al., 1994). In the
further development of MAb 17-lA for treatment human-
mouse chimeric forms of 17-lA have been produced in order
to reduce the human anti-mouse immunoglobulin (HAMA)
response. Chimeric 17-lA IgGI was found to be equally
effective in tumour uptake and in efficacy in radioimmu-
notherapy of tumour-bearing nude mice when compared with
mouse 17-lA (Buchsbaum et al., 1990). In addition, chimeric
17-lA IgGI showed a prolonged circulation time and a
reduced immunogenicity in patients (Meredith et al., 1991).
These data indicate that chimeric 17-lA IgGI may have
advantages for the diagnosis and therapy of cancer.
Another MAb directed against the 17-lA antigen is mouse
323/A3 (Edwards et al., 1986), which recognises an identical
or overlapping epitope but has a higher affinity when
compared with 17-lA (Pak et al., 1991). Although 323/A3
was primarily developed for the diagnosis of breast cancer,
other adenocarcinomas of the colon, ovary, pancreas and
lung showed positive staining with 323/A3 as well (Pak et al.,
1991). In addition, mouse 323/A3 rapidly localised into
human colorectal cancer and breast cancer xenografts in nude
mice (Pak et al., 1991). This high-affinity MAb may therefore
be a good candidate for clinical evaluation.
In this study we compared the MAbs chimeric 17-lA (c-
17-lA) and mouse 323/A3 (m-323/A3) to investigate the
influence of the MAb affinity on tumour uptake and efficacy
of radioimmunotherapy. Both MAbs were analysed in vitro
for their binding characteristics with human ovarian cancer
and colon cancer cells. In vivo, the pharmacokinetics of c-17-
IA and m-323/A3 was determined in non-tumour-bearing
mice, whereas their tumour-targeting properties and efficacy
in radioimmunotherapy were studied in mice bearing human
ovarian cancer xenografts.
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Materials and methods
Cell lines
The human ovarian cancer cell line NIH:OVCAR-3
(OVCAR-3, Hamilton et al., 1983), the human colorectal
cancer cell line WiDr (Chen et al., 1987) and the human
hypopharyngeal cancer cell line UM-SCC-22A (kindly
provided by Dr TE Carey, University of Michigan, Ann
Arbor, MI, USA) were grown as a monolayer in Dulbecco's
modified Eagle medium supplemented with 50 IU ml-1
penicillin, 50 jug ml-' streptomycin and 10% heat-inacti-
vated fetal calf serum. The human leukaemia cell line
CCRF-CEM (Foley et al., 1965) was grown in suspension.
For binding assays, monolayer cells were incubated with
0.2% EDTA in phosphate-buffered saline (PBS) to obtain a
single cell suspension, washed with medium and resuspended
in cold 1% bovine serum albumin (BSA) in PBS.
Animal human tumour model
Female athymic nude mice (Harlan CPB, Zeist, The
Netherlands) were maintained in cages with paper filter
covers under controlled atmospheric conditions. Cages,
covers, bedding, food and water were changed and sterilised
weekly. Animals were handled in a sterile manner in a
laminar down-flow hood. To block the thyroid uptake of free
iodine all animals received 0.1% potassium iodide in their
drinking water during the experiments, starting 3 days before
the injection of radiolabelled MAbs.
The human ovarian cancer xenografts FMa, Ov.Pe and
OVCAR-3 have been described previously (Molthoff et al.,
1991). The FMa xenograft is a poorly differentiated and the
Ov.Pe xenograft is a moderately differentiated mucinous
adenocarcinoma, with a tumour volume doubling time of 5.5
and 8 days respectively.The OVCAR-3 xenograft is a poorly
differentiated serous adenocarcinoma and has a tumour
volume doubling time of 6 days. Xenografts from previous
recipients were transferred by implanting tissue fragments
with a diameter of 2-3 mm into both flanks of 8- to 10-
week-old animals. Upon growth, tumour volume was
measured biweekly in three dimensions and was expressed
in mm3 by the equation length x width x height x 0.5.
Monoclonal antibodies
The MAbs mouse 323/A3 IgGI (m-323/A3) and chimeric 17-
lA IgGI (c-17-1A) are directed against a 38-40 kDa
membrane-associated pancarcinoma glycoprotein (Koprows-
ki et al., 1979; Edwards et al., 1986). The control MAb
chimeric anti-CD4 IgGI (c-anti-CD4) is directed against the
CD4 antigen on human T lymphocytes, whereas the control
MAb mouse E48 IgGl (m-E48) reacts with an antigen
expressed by human squamous and transitional cells and
their neoplastic counterparts (Quak et al., 1989). All MAbs
were kindly provided by Centocor, Leiden, The Netherlands.
Immunohistochemistry
Frozen tissue sections (8 jgm) of FMa, Ov.Pe and OVCAR-3
xenografts were air dried and fixed in cold acetone. Sections
were preincubated with 10% rabbit serum and stained with
MAbs m-323/A3, c-17-lA, m-E48 and c-anti-CD4
(10 jig ml-') in an indirect immunoperoxidase assay. Horse-
radish -peroxidase-conjugated rabbit anti-mouse or anti-
human Ig (Dakopatts, Glostrup, Denmark) were used as
secondary antibodies and freshly prepared diaminobenzidine
hydrochloride, 0.1% in PBS containing 0.02% hydrogen
peroxide was used as chromogen. Sections were counter-
stained with haematoxylin.
Radiolabelling of MAbs
MAbs were labelled with '3'I or 125I with the use of iodogen
(Haisma et al., 1986). In all instances, >97% iodine was
bound to the MAb as measured with trichloroacetic acid
(TCA) precipitation. The sp. act. of the radiolabelled MAbs
varied between 2 and 4 mCi mg-'. The immunoreactive
fractions of the radiolabelled MAbs were determined in a live
cell radioimmunoassay at infinite antigen excess (Lindmo et
al., 1984). The immunoreactive fraction of m-323/A3, using
OVCAR-3 and WiDr cells, was 88% and 90% respectively,
whereas the immunoreactive fraction of c-17-1A varied
between 50% and 65%. The immunoreactivity of the control
MAbs m-E48 and c-anti-CD4, using UM-SCC-22A and
CCRF-CEM cells, was 65% and 60% respectively.
Scatchard analysis
The affinity (Ka) of the radiolabelled MAbs and the number
of binding sites per cell were determined by Scatchard
analysis (Lindmo et al., 1984). Two serial dilutions of
radiolabelled MAb were made, starting at a maximum
concentration of 8 jig ml-' in 1% BSA in PBS, and counted
in a gamma counter to determine the total counts applied. To
calculate the percentage of non-specific binding one serial
dilution of radiolabelled MAbs was mixed with an equal
volume of cells (2 x 106 cells ml-'), which were preincubated
with an excess of unlabelled MAb. The other serial dilution
was mixed with an equal volume of non-preincubated cells.
After a 2 h incubation period at 4°C cells were washed with
cold 1% BSA in PBS and the pellet was counted to determine
the amount of bound MAb. After subtraction of the non-
specific binding and correction for the immunoreactivity of
the radiolabelled MAbs the number of binding sites per cell
and the affinity of the radiolabelled MAb were calculated.
Pharmacokinetics and biodistribution
The blood clearance of m-323/A3 and c-17-lA was
determined in non-tumour-bearing nude mice. Animals
(n=7) were injected i.v. into the eye plexus with a mixture
of [13I]m-323/A3 and ['251]c-17-1A, 5 ,uCi of each MAb. At
5 min, 1, 4, 8, 24, 48 and 120 h after injection, serial eye
bleeding was carried out and the blood samples were counted
in a gamma counter. A standard, prepared from the injected
mixture, was counted simultaneously to correct for the
physical decay of the radionuclides. The percentage of the
injected dose per gram (% ID g-') blood was calculated and
plotted vs time. From the slope of the elimination curve, the
terminal half-lives of the MAbs were determined.
In vivo tissue distribution of the MAbs was performed in
nude mice bearing s.c. FMa, Ov.Pe or OVCAR-3 xenografts.
When tumours had a mean volume of approximately
300 mm3 mice were injected i.v. into the eye plexus with a
mixture of [125I]-m-323/A3 and [13'1]m-E48 or a mixture of
[1251]c-17-lA and ['3'I]c-anti-CD4, 10 piCi of each MAb.
Additional biodistribution experiments with the higher
radiation doses of ['3'I]m-323/A3 and ['311]c-17-lA used in
the treatment experiments were performed in mice bearing
tumours of a mean volume of 100-150 mm3. At several time
points, three mice per group were bled and sacrificed.
Tumours, blood and normal organs (heart, lung, sternum,
liver, spleen, stomach, ileum, colon, kidney, bladder, muscle,
skin, fat) were collected, weighed and counted in a gamma
counter. The % ID g-1 tissue, corrected for the physical
decay of the radionuclides, was then calculated and plotted vs
time. From the area under the curve (AUC), the absorbed
cumulative radiation doses were calculated using the
trapezoid integration method. These doses were expressed
in cGy by multiplying the integrated ,uCi h g-1 by the g cGy
uCi- h-1 factor for 131I (0.3985: Dillman, 1969), assuming a
similar distribution pattern for 1251- and "3'I-labelled MAbs.
The distribution of m-323/A3 and c-17-lA in tumour
tissue was visualised by macroautoradiography. Tumours
were quickly frozen in liquid nitrogen. Of each MAb, three
tumours per time point were selected for autoradiography.
Cross sections of 8 ,um were cut, air dried and fixed in cold
acetone. Sections were exposed to a phosphor plate for 2-4
days and analysed by a phosphor imager service (B&L-Isogen
Service Laboratory, Amsterdam, The Netherlands). Subse-quently, sections were stained with haematoxylin. Based on
the histological appearance (absence of necrosis and artifacts,
presence of tumour capsule), one section per time point was
selected for further autoradiographic analysis. A cross line
was drawn through the centre of the tumour and the
radioactivity along this line was measured. The results were
plotted in an activity density profile as radioactivity vs
diameter.
Radioimmunotherapy
Treatment of mice bearing FMa, OVCAR-3 or Ov.Pe
xenografts was initiated when tumours had a mean volume
of 100- 150 mm3 (day 0). Control and treatment groups
consisted of 5-6 animals. Mice were injected i.v. at days 0
and 14 into the eye plexus either with ['31I]m-323/A3 or
[311I]c-17-4A. The specific activity of the MAbs was 3.4-3.6
mCi mg-'. Equivalent radiation doses, based on the
immunoreactivity of the MAbs after radiolabelling, were
given to two groups. Another treatment group received an
adjusted radiation dose of [13'I]m-323/A3 or [131I]c-17-IA in
order to compare the effect of similar amounts of radiation in
the tumour. This adjustment was calculated on the basis of
the lower tumour uptake of c-17-IA when compared with
that of m-323/A3. Tumours were measured biweekly for a
period of 2-3 months or until the tumours had become too
large (>2500 mm3). The results were plotted as the tumour
volume at a given day relative to the tumour volume at day 0
vs time after the initiation of the treatment. The therapeutic
efficacy of [1`I]m-323/A3 and [1311]c-17-IA was expressed as
the percentage of growth inhibition in treated tumours with
respect to control tumours at day 35 after the initiation ofthe
treatment.
Whole body radiation doses were measured daily using a
dose calibrator VDC-101 (Veenstra, Eext, The Netherlands).
From the area under the curve, similar calculations as
described for the in vivo distribution of MAbs were carried
out to express the whole body absorbed radiation dose in
cGy.
Statistical analysis
The data of the biodistribution assays were statistically
analysed with the use of the multivariate linear model
(MANOVA). Differences in therapeutic efficacy between
['3'I]m-323/A3 and ["3'I]c-17-IA were analysed with Student's
t-test for unpaired data.
Results
Scatchard analysis
The binding characteristics of m-323/A3 and c-17-IA were
determined by Scatchard analysis, using OVCAR-3 and
WiDr cells (Table I). At 4°C both MAbs reacted with a
similar number of binding sites per cell. The affinity of m-
323/A3 varied from 1.3 to 3.0 x 109 M-', which was
approximately 5-fold higher than the affinity of c-17-IA
(3.0-5.4 x 10 M-1). When the temperature was increased to
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37°C no binding of c-17-lA could be observed, whereas m-
323/A3 was not affected in its binding.
Competition assays were performed at 4°C, in which
['25I]m-323/A3 was mixed with WiDr cells preincubated with
unlabelled c-17-1A, and ['251I]c-17-IA was mixed with WiDr
cells preincubated with unlabelled m-323/A3 (Figure 1). MAb
m-323/A3 completely blocked the binding of c-17-IA to
tumour cells, whereas c-17-lA could not inhibit the binding
of m-323/A3. Similar results were obtained with the use of
OVCAR-3 cells.
Antigen expression in xenografts
The antigen distribution in FMa, Ov.Pe and OVCAR-3
xenografts was visualised in an indirect immunoperoxidase
assay, in which frozen tumour sections were incubated with
m-323/A3, c-17-1A, m-E48 and c-anti-CD4. MAb m-323/A3
stained the membrane and the cytoplasm of all tumour cells
in the three xenografts in a moderate to strong manner. MAb
c-17-IA also stained the membrane and the cytoplasm of
tumour cells, but the intensity of the staining was moderate
to weak when compared with that of m-323/A3. The control
MAbs m-E48 and c-anti-CD4 did not react with the
xenografts.
Pharmacokinetics and biodistribution
The blood clearance of m-323/A3 and c-17-IA was
investigated in non-tumour-bearing nude mice. No signifi-
cant differences in the pharmacokinetics between the MAbs
could be observed. The initial half-lives of m-323/A3 and c-
17-lA were 10.9+4.4 h and 12.5+5.0 h, whereas the
terminal half-lives (calculated from 8 to 120 h) were
71.4+ 13.8 h and 62.7+ 12.6 h, respectively.
The biodistribution of m-323/A3 and c-17-IA was
determined in mice bearing FMa, OVCAR-3 or Ov.Pe
xenografts. The retention of both MAbs and their control
c
.0
0
0.0 0.8 1.6 2.4 3.2 4.0
MAb (gg ml-1)
Figure 1 Competition assay of m-323/A3 and c-17-IA with the
use of WiDr cells: 0, specific binding of [1251)m-323/A3;
specific binding of [12511]c-17-1A; 0, binding of [1 5I]m-323/A3 to
cells preincubated with unlabelled c-17-lA; *, binding of ['251]c-
17-lA to cells preincubated with unlabelled m-323/A3.
Table I Cellular binding characteristics of m-323/A3 and c-17-lA
Temperature Sites cell- K (M-1)
Cell line MAb (°C) x105 (±s.d.) xJOR (+s.d.)
OVCAR-3 m-323/A3 4 16.7 (+ 1.4) 13.0 (± 1.0)
WiDr m-323/A3 4 6.0 ( 1.4) 30.0 (i8.0)
OVCAR-3 c-17-IA 4 10.0 (+2.1) 3.0 (+0.7)
WiDr c-17-IA 4 5.4 (+ 1.3) 5.4 (+0.9)
OVCAR-3 m-323/A3 37 13.0 (+3.8) 11.0 (+2.0)
WiDr m-323/A3 37 11.0 (±2.0) 13.0 (+3.0)
OVCAR-3 c-17-IA 37 No binding
WiDr c-17-IA 37 No binding
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MAbs m-E48 and c-anti-CD4 in blood and the uptake in
tumour tissue and liver are shown in Figure 2. Specific
uptake of m-323/A3 was observed in FMa, OVCAR-3 and
Ov.Pe xenografts when compared with the control MAb m-
E48 (P<0.01). MAb c-17-IA localised specifically in the
FMa xenograft (P<0.01) but the uptake in OVCAR-3 and
Ov.Pe xenografts was only slightly higher than that of c-anti-
CD4. MAbs m-323/A3 and c-17-lA and their control MAbs
localised to a similar extent in the liver. In other normal
organs uptake of the MAbs was equal to or lower than the
uptake in the liver.
The cumulative absorbed radiation doses delivered by
10 MCi of m-323/A3, c-17-lA, m-E48 and c-anti-CD4 in
blood, tumour, liver, spleen and kidney were calculated from
the data of the biodistribution experiments (Table II). The
absorbed doses in blood exceeded those in the tumours,
except for m-323/A3 in mice bearing FMa xenografts. The
radiation dose delivered by m-323/A3 to FMa, OVCAR-3
and Ov.Pe xenografts was 4.7-, 2.6- and 2.5-fold, respectively,
higher than that delivered by c-17-lA. The liver, spleen and
kidney received similar low doses of m-323/A3 and c-17-lA,
which were similar to those delivered by m-E48 and c-anti-
CD4.
The distribution pattern ofm-323/A3 and c-17-lA in FMa
and OVCAR-3 xenografts was visualised by autoradiogra-
phy. MAb m-323/A3 was heterogeneously distributed in FMa
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Figure 2 Percentage of injected dose per gram tissue of iodinated m-323/A3 (0), c-17-IA (O), m-E48 (@) and c-anti-CD4 (0) in
blood, tumour and liver of mice bearing FMa, OVCAR-3 or Ov.Pe xenografts. Note: use of a different scale for the uptake of
MAbs in FMa tumour tissue.
Table II Cumulative absorbed radiation doses in blood, tumours and normal organs of nude mice bearing human ovarian cancer xenograftsa
Blood Tumour Liver Spleen Kidney
FMa
m-323/A3 36 165 4 4 5
c-17-IA 45 35 8 10 7
m-E48 63 15 10 8 10
c-anti-CD4 56 16 11 13 9
OVCAR-3
m-323/A3 54 31 8 6 9
c-17-IA 46 12 5 5 7
m-E48 64 10 9 7 11
c-anti-CD4 48 7 6 5 7
Ov. Pe
m-323/A3 48 33 7 4 7
c-17-1A 44 13 4 4 6
m-E48 54 12 7 5 8
c-anti-CD4 49 8 5 5 7
aAbsorbed doses were determined from the data of the biodistribution experiments and are expressed in cGy per 10 ,Ci radiolabelled MAb,
calculated over 0- 168 h. The % ID g in blood at 0 h was derived from the data ofthe pharmacokinetics in non-tumour-bearing nude mice. The
% ID g-1 in tumour, liver, spleen and kidney at 0 h was assumed to be 0%.
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xenografts, whereas c-17-IA showed a more homogeneous
pattern (Figure 3). This phenomenon was observed 24 h after
injection and did not change noticeably in the following 3
days. The radioactivity density profiles illustrate the
differences in uptake and in distribution between both
MAbs. Owing to the lower uptake of m-323/A3 and c-17-
IA in OVCAR-3 xenografts, it was more difficult to observe
a difference in the distribution between the antibodies, but
again m-323/A3 was heterogeneously distributed throughout
the tumour (Figure 4).
Radioimmunotherapy
In previously performed maximum tolerated dose (MTD)
studies the MTD in OVCAR-3 and Ov.Pe xenografts was
400 juCi [13I]m-323/A3 i.v. given twice with a 2 week interval,
whereas in FMa xenografts this was 250,Ci. These doses
were based on the occurrence of 10- 15% weight loss, from
which mice had recovered by day 28. Since treatment of FMa
xenografts with 100 uCi ["3'I]m-323/A3 caused complete
tumour regressions, this radiation dose had to be reduced
to 50 ,uCi in the treatment experiments.
The tumour growth of control mice and mice treated with
['31I]m-323/A3 or ['31I]c-17-lA is shown in Figure 5. When
mice were treated with equivalent radiation doses the growth
inhibition induced by ['31I]m-323/A3 and calcualted at day 35
in FMa and Ov.Pe xenografts was better when compared
with that of [1311]c-17-lA (P<0.05, Table III). No difference
in growth inhibition was observed in OVCAR-3 xenografts.
When corrections were made for the tumour uptake, meaning
that a 4.7-fold higher radiation dose of [1311]c-17-IA was
injected in FMa-bearing mice and a 2.5- and 2.6-fold lower
radiation dose of [31I]m-323/A3 in Ov.Pe- and OVCAR-3-
bearing mice, [1311]c-17-lA was more effective in tumour
growth inhibition in all three xenografts (P<0.05). Especially
in FMa xenografts, ['311]c-17-IA could induce a growth
inhibition of 99% and complete remissions were observed in
four of nine tumours. Additional biodistribution experiments
with doses of [131I]m-323/A3 and ['311]c-17-lA adjusted to
obtain an equivalent amount of radiation in the tumour
confirmed the similarity in absorbed radiation doses (Table
III).
Whole-body radiation doses in treated mice were measured
up to 4 weeks after the initiation of the treatment. No
significant difference in the whole-body clearance was
observed between [13I]m-323/A3 and ['311]c-17-lA in mice
bearing FMa or OVCAR-3 xenografts, whereas a slightly
faster clearance of [1311]c-17-4A was observed in Ov.Pe-
bearing mice. The effective whole-body half-life (+s.e.m.) of
['31I]m-323/A3 in FMa-, OVCAR-3- and Ov.Pe-bearing mice
was 70+2.8 h, 84+ 14 h and 109+8 h, respectively, whereas
this was 99+ 17 h, 77+8.3 h and 77+7 h, respectively, for
['3'I]c-17-lA. These half-lives were independent of the doses
administered. The whole-body absorbed radiation doses were
in agreement with the radiation dose administered.
As both m-323/A3 and c-17-IA are able to induce ADCC,
the therapeutic effect of unlabelled m-323/A3 and c-17-lA
was studied in FMa-bearing mice using the same injection
schedule as in the radioimmunotherapy experiments. When
mice were treated with m-323/A3 or c-17-lA at protein doses
exceeding those used in the radioimmunotherapy experiments
(200 ,ug) no tumour growth inhibition was induced by either
MAb.
Discussion
In the present study we demonstrated that the high-affinity
MAb m-323/A3 targeted better to tumour tissue, but was
more heterogeneously distributed when compared with the
low-affinity MAb c-17-lA. When mice were treated with
equivalent radiation doses of ['31I]m-323/A3 and ['31I]c-17-1A,
['3'I]m-323/A3 induced a better growth inhibition in FMa and
Ov.Pe xenografts. However, when radiation doses were
adjusted to obtain equivalent amounts of radiation in the
tumour, [1311]c-17-lA induced a better growth inhibition in all
three xenografts.
The in vitro binding studies demonstrated an important
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Figure 3 Autoradiographs (magnification 5 x ) and the corre-
sponding radioactivity density profiles of 10 MCi [125I]m-323/A3
(a) and ['251]c-17-IA (b) in the FMa xenograft 24h after
administration (% ID g-1 was 42% for m-323/A3 and 9% for
c-17-lA). Note: use of a larger area in (b) to obtain a better
qualitative activity-density profile.
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Figure 4 Autoradiographs (magnification 4 x) and the corre-
sponding radioactivity density profiles of 101Ci [125I]m-323/A3
(a) and [1251]c-17-1A (b) in the OVCAR-3 xenograft 24h after
administration (% ID g- was 11.4% for m-323/A3 and 4.4% for
c-17-lA).
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role for temperature in the binding capacity of c-17-1A. At
4°C, Scatchard analysis showed a 5-fold higher affinity for m-
323/A3 when compared with c-17-lA, whereas the number of
Equivalent radiation dose
E
ci
C's
+,
-5 0
E
_
ci)
Cu
100
10
u. I-
-10
FMa
.4
r-~~~~~~~~
. 1 >FIt.
_
0 10 20 30 40 50 60
binding sites per cell was similar for both MAbs. Similar or
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1992; Oredipe et al., 1992). At 37°C we observed no binding
of c-17-lA, whereas the binding of m-323/A3 was not
affected. Lower binding of 17-1A with increasing tempera-
ture has been reported before (Oredipe et al., 1992; Langmuir
et al., 1992). Changes in membrane fluidity at 37°C resulting
in a physical barrier for 17-lA to bind to its epitope could be
the cause of the reduced binding of 17-lA, as was suggested
by the group of Langmuir. In vivo, however, we could still
demonstrate specific uptake of c-17-lA in human ovarian
cancer xenografts.
Competition assays at 4°C showed a complete inhibition
of the binding of c-17-IA to tumour cells by m-323/A3,
whereas m-323/A3 was still able to bind to tumour cells that
were preincubated with c-17-1A. This phenomenon has been
reported before (Pak et al., 1991; Langmuir et al., 1992) and
can be explained by the different affinities. In addition,
Langmuir et al. (1992) suggested that the binding site for c-
17-lA may be masked when m-323/A3 is bound to its
epitope, whereas the occupation of the binding site for c-17-
IA does not hamper the binding of m-323/A3.
In comparison with c-17-lA, m-323/A3 showed a more
intense staining pattern in frozen sections of all three human
ovarian cancer xenografts. The stronger reactivity of 323/A3
may be due to its higher affinity, but other factors could also
explain the difference in staining intensity. First, the epitope
for 17-lA is known to be sensitive for fixatives (Herlyn et al.,
1986), which may result in a decrease in binding sites for c-
17-lA during the processing for immunohistochemistry.
Second, a different glycosylated form of the antigen may be
expressed in some tumour types, which can be recognised by
m-323/A3 but not by c-17-IA (Velders et al., 1994). In
addition, Thampoe et al. (1988) have described two forms of
the antigen, a single chain of 38 kDa with a disulphide-linked
intramolecular loop, and a derived disulphide-linked dimer
consisting of a 32 kDa and a 6 kDa subunit. Both forms may
be recognised by m-323/A3 but not by c-17-1A.
MAb m-323/A3 targeted better to tumour tissue than c-17-
1A. The cumulative absorbed radiation doses in FMa,
OVCAR-3 and Ov.Pe xenografts delivered by m-323/A3
were higher than those delivered by c-17-lA, even when
corrections were made for the immunoreactive fractions of
the MAbs after radiolabelling. Also, m-323/A3 remained
longer in tumour tissue than c-17-lA. These results can most
likely be explained by the extreme difference in affinity
between both MAbs at 37°C. However, other factors such as
differences in the quantity and accessibility of the epitopes
could have an effect on the tumour uptake as well.
Autoradiography showed a heterogeneous distribution
pattern of a low protein dose of m-323/A3 in tumour
tissue, whereas c-17-1A was more homogeneously distributed.
These findings are in agreement with the hypothesis of a
perivascular binding for high-affinity MAbs and a deeper
penetration for low-affinity MAbs in tumour tissue (Juweid et
al., 1992).
Although m-323/A3 showed a similar strong reactivity
pattern with frozen sections of all three human ovarian
cancer xenografts in vitro, the tumour uptake of m-323/A3 in
vivo varied between the xenografts. Blumenthal et al. (1992a)
have also found a variation in uptake of a radiolabelled anti-
CEA MAb in different human colon cancer xenografts, which
was most likely due to differences in the intratumoral and
intracellular distribution of CEA. We found m-323/A3
staining of the membrane and the cytoplasm of tumour
cells throughout the whole xenograft tissue sections,
indicating a homogeneous distribution of the antigen. To
obtain more insight into the differences in the uptake of m-
323/A3 in these xenografts, we are currently analysing other
factors of influence, including tumour perfusion, tumour
vascularisation pattern and the antigen content.
In our treatment experiments mice were injected with
doses of ['311]c-17-IA and [I3II]m-323/A3, which were adjusted
to be equivalent in radiation or equivalent in tumour uptake.
MAb ['3'I]m-323/A3 was superior in growth inhibition in two
xenografts when compared with an equivalent radiation dose
of ['3'I]c-17-lA. This is most likely a result of the higher
uptake of m-323/A3 in these xenografts. When similar
absorbed radiation doses in the tumours were obtained a
superiority in growth inhibition was observed for ['31I]c-17-
1A in all three xenografts. We expect the deeper tumour
penetration of c-17-lA resulting in a more homogeneous
distribution of radiation as the most likely explanation for
the better efficacy of ['311]c-17-lA. Although the whole-body
absorbed radiation dose was higher in mice treated with
['31I]c-17-lA, this was not expected to have a therapeutic
effect on the s.c. tumours. In small animals there is virtually
no self-absorption of y-rays (Wahl, 1994). Therefore, tumour
growth inhibition induced by '3'1-labelled MAbs can mostly
be attributed to tumour-absorbed fl-particles, which have a
mean range of 0.8 mm (Jurcic and Scheinberg, 1994).
The effect of MAb affinity on the efficacy of radio-
immunotherapy has been studied before, but the preference
for low- or high-affinity MAbs was still elusive. In vivo, better
tumour-targeting properties have been reported for a high
affinity anti-CEA MAb (Hansen et al., 1993), but the MAb
was equally effective in radioimmunotherapy when compared
with a similar radiation dose of a low-affinity anti-CEA MAb
(Blumenthal et al., 1992b). In this study no corrections were
made for the immunoreactivity of the MAbs after radiolabel-
ling. Other in vivo studies have reported an improved
localisation as well as a therapeutic advantage for radi-
olabelled high-affinity MAbs against the TAG-72 antigen
when compared with a low affinity anti-TAG-27 MAb
(Colcher et al., 1988; Schlom et al., 1992). Even with a 2.5-
to 3-fold lower radiation dose of the high-affinity MAbs,
which might compensate for the lower amount of absorbed
radiation dose delivered by the low-affinity MAb, better anti-
tumour effects were observed for the high-affinity MAbs. This
is in contrast with the present experiments, in which we
clearly show that the low-affinity MAb c-17-lA is superior to
the high-affinity MAb m-323/A3 in tumour growth inhibition
when similar amounts of radiation are delivered to the
tumour. Nevertheless, 323/A3, preferably in the chimeric
form, may be favourable for use in radioimmunotherapy as
higher radiation doses of c-17-lA required to obtain similar
or better anti-tumour effects will be associated with increased
side-effects. In addition, m-323/A3 targets better to tumour
tissue and may therefore be more efficient in immunoscinti-
graphy of tumour lesions in patients.
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